GLP-1受体激动剂与2型糖尿病合并糖尿病视网膜病变患者全身及眼部血管并发症风险
这项回顾性人群队列研究基于TriNetX数据库2015至2022年数据,纳入173,216例2型糖尿病合并糖尿病视网膜病变成人,经倾向评分匹配后比较使用与未使用GLP-1受体激动剂者的结局。结果显示GLP-1受体激动剂使用与心肌梗死、心衰加重、缺血性卒中、急性肾损伤、肾脏替代治疗、增殖性糖尿病视网膜病变、视网膜静脉阻塞及新生血管性青光眼风险降低相关,与视网膜动脉阻塞及非动脉炎性前部缺血性视神经病变无显著关联。
要点
- 在2型糖尿病合并糖尿病视网膜病变患者中,GLP-1受体激动剂使用与主要大血管及微血管并发症风险降低相关。
- 眼部方面,增殖性糖尿病视网膜病变、视网膜静脉阻塞及新生血管性青光眼风险降低,视网膜动脉阻塞及非动脉炎性前部缺血性视神经病变无显著关联。
- 该研究为回顾性队列,尚需未来研究评估GLP-1受体激动剂对长期结局的获益程度。
核心结论
- 在2型糖尿病合并糖尿病视网膜病变患者中,使用GLP-1受体激动剂与主要大血管和微血管并发症风险降低相关,包括直接影响视网膜的并发症。
研究设计与样本
- 纳入173,216例年龄≥18岁、糖化血红蛋白≥6.5%且既往诊断为糖尿病视网膜病变的2型糖尿病成人。
- 根据是否至少间隔6个月接受至少2次GLP-1受体激动剂处方(司美格鲁肽、度拉糖肽、利拉鲁肽、艾塞那肽、替尔泊肽或利司那肽)进行倾向评分匹配调整基线特征。
- 采用Cox比例风险回归模型评估2年随访期间新发大血管和微血管并发症风险。
- 倾向评分匹配后,30,613例被处方GLP-1受体激动剂,平均(标准差)年龄61.6(11.4)岁,53.2%为女性。
主要发现
- 使用GLP-1受体激动剂者心肌梗死风险降低(HR 0.65;95%CI 0.61-0.69)。
- 冠状动脉血运重建手术风险降低(HR 0.75;95%CI 0.67-0.84),心力衰竭加重风险降低(HR 0.78;95%CI 0.76-0.81)。
- 缺血性卒中风险降低(HR 0.78;95%CI 0.74-0.83),下肢截肢风险降低(HR 0.78;95%CI 0.69-0.88)。
- 急性肾损伤风险降低(HR 0.68;95%CI 0.66-0.71),需要肾脏替代治疗的风险降低(HR 0.40;95%CI 0.36-0.43)。
- 进展为增殖性糖尿病视网膜病变的风险降低(HR 0.78;95%CI 0.71-0.86),视网膜静脉阻塞风险降低(HR 0.70;95%CI 0.61-0.80),新生血管性青光眼风险降低(HR 0.65;95%CI 0.47-0.89);视网膜动脉阻塞(HR 0.85;95%CI 0.57-1.26)及非动脉炎性前部缺血性视神经病变(HR 0.88;95%CI 0.54-1.44)无显著关联。
临床怎么用
- 对于2型糖尿病合并糖尿病视网膜病变患者,GLP-1受体激动剂的使用可能与全身大血管、微血管及部分视网膜并发症风险降低相关,可作为综合管理时考虑的降糖药物选择之一。
- 该研究为回顾性观察性研究,不能确立因果关系,临床决策仍需结合患者个体情况及随机对照试验证据。
局限性
- 研究为回顾性、基于数据库的队列研究,可能存在未测量混杂因素。
- 研究仅评估2年随访期间的结局,长期获益尚需未来研究评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use on macrovascular and microvascular outcomes in patients with type 2 diabetes (T2D) and diabetic retinopathy (DR)-a high-risk group often excluded from clinical trials. DESIGN: Retrospective, population-based cohort study. PARTICIPANTS: Adults aged ≥18 years with T2D (with hemoglobin A1c of ≥6.5%) and a pre-existing diagnosis of DR from the TriNetX research network database between January 1, 2015, and December 31, 2022. METHODS: The study included 173,216 adults with T2D, all of whom had DR, adjusted for baseline characteristics through propensity score matching (PSM) based on whether the individuals received at least 2 prescriptions of a GLP-1 RA (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide, or lixisenatide) at least 6 months apart. MAIN OUTCOME MEASURES: Cox proportional hazard regression models were used to evaluate the association between GLP-1 RAs and the risk of incident macrovascular and microvascular complications over a 2-year follow-up period. RESULTS: After PSM, 30,613 individuals (mean [SD] age, 61.6 [11.4] years; 53.2% were females) were prescribed GLP-1 RAs. Patients on GLP-1 RAs had a decreased risk of myocardial infarctions (MIs; hazard ratio [HR], 0.65; 95% CI, 0.61-0.69), coronary artery revascularization procedures (HR, 0.75; 95% CI, 0.67-0.84), heart failure exacerbations (HR, 0.78; 95% CI, 0.76-0.81), ischemic strokes (HR, 0.78; 95% CI, 0.74-0.83), lower extremity amputations (HR, 0.78; 95% CI, 0.69-0.88), acute kidney injuries (AKI; HR, 0.68; 95% CI, 0.66-0.71), or the need for renal replacement therapy (RRT; HR, 0.40; 95% CI, 0.36-0.43). Fewer individuals also progressed to proliferative diabetic retinopathy (HR, 0.78; 95% CI, 0.71-0.86), experienced retinal vein occlusions (RVOs; HR, 0.70; 95% CI, 0.61-0.80), or developed neovascular glaucoma (HR, 0.65; 95% CI, 0.47-0.89); no association was observed for retinal artery occlusions (RAOs; HR, 0.85; 95% CI, 0.57-1.26) or cases of non-arteritic ischemic optic neuropathy (NAION; HR, 0.88; 95% CI, 0.54-1.44). CONCLUSIONS: In patients with T2D and pre-existing DR, the use of GLP-1 RAs was associated with a reduced risk of major macrovascular and microvascular complications, including those directly affecting the retina. Future studies are needed to assess the extent to which GLP-1 RAs benefit long-term outcomes.
引用
- Shah J, Makwana B, Panchal K, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy. Am J Ophthalmol. 2026. PMID: 42025665. doi:10.1016/j.ajo.2026.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。